A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS
Status:
Recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
This is a two Part study in patients with relapsed/refractory acute myeloid leukemia (AML),
chronic myelomonocytic leukemia (CMML), or high risk myelodysplastic syndrome (MDS) that will
initially evaluate the safety and tolerability of APG-115 as a single agent in Part 1,
followed by a combination of APG-115 + 5-azacitidine (5-AZA) in Part 2.